Evidence map›Paper›PMID 39938488›Full record

ReviewRespiration; international review of thoracic diseases2025

Pulmonary Hypertension in the Field of Hematological and Oncological Diseases.

Mona Lichtblau, Frédéric Lador, Benoit Lechartier, Jana Maria Ellegast, Susanne Pohle, Helga Preiss, Leon Genecand, Carmen Wick, Silvia Ulrich, Lena Reimann

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Respiration; international review of thoracic diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mona LichtblauDepartment of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
Frédéric LadorPulmonary Hypertension Program, University Hospitals of Geneva, Geneva, Switzerland.
Benoit LechartierPulmonary Division, Lausanne University Hospital, Lausanne, Switzerland.
Jana Maria EllegastFaculty of Medicine, University of Zurich, Zurich, Switzerland.
Susanne PohleLung Center, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Helga PreissDepartment of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
Leon GenecandPulmonary Hypertension Program, University Hospitals of Geneva, Geneva, Switzerland.
Carmen WickDepartment of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
Silvia UlrichDepartment of Pulmonology, University Hospital Zurich, Zurich, Switzerland.
Lena ReimannDepartment of Pulmonology, University Hospital Zurich, Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHematological and oncological diseases collectively affect a substantial number of patients. Pulmonary hypertension (PH) is recognized as a potential rare complication associated with these conditions, manifesting in various forms of PH and presenting with a range of symptoms. This review aimed to summarize recent research findings and enhance the understanding of the complex interactions between PH and hemato-oncological diseases.

methodsThis narrative review synthesizes recent research findings to explore the interplay between PH and hematological or oncological diseases. A comprehensive search of relevant literature was conducted using PubMed.

resultsThe complexity of PH in this context arises from its multifactorial etiology, which can include direct effects of malignancies, treatment-related effects, and the impact of disease progression. The variability in how PH presents and progresses in patients with hematological diseases and neoplasms complicates its diagnosis and management. Accurate identification of PH alongside the underlying condition is crucial for enabling optimal treatment and improving overall survival. A multidisciplinary approach is essential to address these challenges effectively.

conclusionPH in hematologic and oncologic diseases can result from multiple causes. Following a systematic workup, a multidisciplinary approach to management is crucial to ensure optimal treatment and improve survival.

Indexed as

Hematologic DiseasesHypertension, PulmonaryNeoplasmsHematologic NeoplasmsHumansCancerHematological pulmonary hypertensionPulmonary hypertensionTumoral pulmonary hypertension

Identifiers

PMID39938488
PMCPMC12215174

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.